抗EGFR-抗CD3双功能抗体介导CIK细胞、LAK细胞或PBLS细胞对胃癌荷瘤裸鼠治疗效果的比较

 目的　比较抗EGFR-抗CD3双功能抗体在体内条件下介导CIK细胞、LAK细胞及人类PBLS细胞三类不同的免疫效应细胞对胃癌细胞的杀伤能力，为临床应用该抗体治疗胃癌的细胞选择提供实验指导。方法　采用化学耦联法合成的抗EGFR-抗CD3双功能抗体分别与CIK细胞、LAK细胞及人类PBLS细胞联合经尾静脉注入SGC7901胃癌细胞移植瘤小鼠体内，同时以等量0.9 % NaCl溶液尾静脉注射建立对照，治疗后检测在体情况下4组对胃癌细胞的杀伤能力，进行组间比较。结果　抗EGFR-抗CD3双功能抗体介导CIK细胞治疗组小鼠肿瘤抑制率为（64.9±7.7）%，显著高于抗EGFR-抗CD3双功能抗体介导LAK细胞及人类PBLS细胞组的（43.5±8.2）%和（39.7±6.5）%（均P＜0.05），治疗结束时平均肿瘤质量为（473.9±37.7）mg，显著低于其他两组的（764.6±88.3）mg和（829.1±104.4）mg（均P＜0.05）。结论　初步的裸鼠模型治疗实验显示由抗EGFR-抗CD3双功能抗体介导的CIK细胞在体内条件下对胃癌治疗作用优于其他常用的免疫效应细胞。

Comparison of the immunotherapy of the CIK cell, LAK cell and PBLS cell mediated by anti-EGFR/anti-CD3 bispecific antibody on the mice borne human gastric cancer

Objective To investigate the effect of the immunotherapy of CIK cell, LAK cell and PBLS cell mediated by anti-EGFR/anti-CD3 bispecific antibody （BsAb） respectively on the mice borne human gastric cancer and provide experimental evidence for therapeutic strategy in treating gastric cancer. Methods The mAbs of anti-CD3 and anti-EGFR were cross-linked to prepare the BsAb by chemical synthesis. The experimental therapy on the mice borne SGC7901 human gastric cancer was performed, and then the comparisons of the curative activity among the CIK group, LAK group and PBLS group were conducted in vivo. Results The mean tumor reduction rate of the administration of CIK cells directed by anti-EGFR/anti- CD3 BsAb was （64.9±7.7） % and higher than those of LAK cells or PBLS targeted by anti-EGFR/anti-CD3 BsAb （43.5±8.2） % and （39.7±6.5） %] （P 〈 0.05）. The mean tumor weight of the administration of CIK ceils directed by anti-EGFR/anti-CD3 BsAb was （473.9±37.7） mg at the end of therapy and was lower than those of LAK cells or PBLS targeted by anti-EGFR/anti-CD3 BsAb （764.6±88.3） mg and （829.1±104.4） mg] （P 〈 0.05）. Conclusion The CIK cell mediated by anti-EGFR/anti-CD3 BsAb could have better curative effect than other effector cells on gastric cancer in vivo.